Apidra Savings Program

Based on the information you have provided, you may be eligible to use the Apidra (insulin glulisine) 100 units/mL Savings Card. This card may help you pay as little as $0 per 30-day prescription for up to a maximum savings of $100, based on your insurance.

Co-pay cards can help lower the out-of-pocket amount you pay at the pharmacy counter because you have commercial insurance. You must have a valid prescription for this product. Your insurance may choose to only count what you pay out-of-pocket towards your deductible, if you have one. 

  • Click here: https://www.apidra.com/savings to download the Apidra Savings Card.
  • Provide this information to the pharmacy (in person or by telephone) so they can add this Apidra Savings Card to their payment system before you pick up your prescription.

If you have questions about the savings card, please call 1-866-251-4750 between 8AM and 8PM ET, Monday through Friday (excluding holidays).

Additional Resources

About Getinsulin.org

GetInsulin.org is a resource for those struggling to access insulin today. Since 2013, the list price of insulin has skyrocketed, leaving some without health insurance or on high-deductible insurance plans paying out-of-pocket upwards of $1,000 for a one-month supply of insulin, often unaware of assistance options. This is the result of a unique drug pricing crisis going on in the United States that will require widespread healthcare reform to bring list prices down. In the immediate term, people in the US need to know what their options are to access insulin.

GetInsulin.org is a program of Beyond Type 1, an organization that advocates for high quality, modern insulin to be available to people with diabetes regardless of employment or insurance status, across all demographics, without barriers, and at an affordable and predictable price point. Until that is achieved, GetInsulin.org is a tool for those needing access to insulin options immediately.

Sponsors

GetInsulin.org is a resource of Beyond Type 1 with support from Lilly, Novo Nordisk, and Sanofi